Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease

被引:11
作者
Cazzola, M
Di Perna, F
Centanni, S
Califano, C
Donner, CF
D'Amato, M
D'Amato, G
机构
[1] A Cardarelli Hosp, Div Pneumol & Allergol, Naples, Italy
[2] Univ Milan, Sch Med, San Paolo Hosp, Resp Dis Unit, Milan, Italy
[3] S Maugeri Fdn, Inst Care & Res, Med Ctr Rehabil, Div Pneumol, Veruno, Italy
关键词
salmeterol; oxitropium bromide; combination therapy; chronic obstructive pulmonary disease;
D O I
10.1136/thx.54.12.1083
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background-An earlier study documented that, in patients with chronic obstructive pulmonary disease (COPD), addition of ipratropium bromide at the clinically recommended dose (40 mu g) does not produce any further bronchodilation than that achieved with salmeterol 50 mu g alone. However, the dose of ipratropium bromide needed to produce near maximal bronchodilation is several times higher than the customary dosage. The full therapeutic potential of combined salmeterol plus an anticholinergic drug can therefore only be established using doses higher than those currently recommended in the marketing of these agents. A study was undertaken to examine the possible acute effects of higher than conventional doses of an anticholinergic agent on the single dose salmeterol induced bronchodilation in patients with stable and partially reversible COPD. Methods-Thirty two outpatients received 50 pg salmeterol or placebo. Two hours after inhalation a dose-response curve to inhaled oxitropium bromide (100 mu g/puff) or placebo was constructed using one puff, one puff, two puffs, and two puffs-that is, a total cumulative dose of 600 mu g oxitropium bromide. Dose increments were given at 20 minute intervals with measurements being made 15 minutes after each dose. On four separate days all patients received one of the following: (1) 50 pg salmeterol + 600 pg oxitropium bromide; (2) 50 pg salmeterol + placebo; (3) placebo + 600 pg oxitropium bromide; (4) placebo + placebo. Results-Salmeterol induced a good bronchodilation (mean increase 0.272 1; 95% CI 0.207 to 0.337) two hours after its inhalation. Oxitropium bromide elicited an evident dose-dependent increase in forced expiratory volume in one second (FEV1) and this occurred also after pretreatment with salmeterol with a further mean maximum increase of 0.152 1 (95% CI of differences 0.124 to 0.180). Conclusions-This study shows that acute pretreatment with 50 pg salmeterol does not block the possibility of inducing more bronchodilation with an anticholinergic agent when a higher than normal dosage of the muscarinic antagonist is used.
引用
收藏
页码:1083 / 1086
页数:4
相关论文
共 50 条
[31]   An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease [J].
Hogan, TJ ;
Geddes, R ;
Gonzalez, ER .
CLINICAL THERAPEUTICS, 2003, 25 (01) :285-297
[32]   Thymopentin and salmeterol-fluticasone for moderate to severe chronic obstructive pulmonary disease and its effect on IgE expression [J].
Li, Shuyue ;
Zhu, Qifang ;
Zhang, Lei ;
Xu, Pengfei ;
Geng, Jifei ;
Dong, Yiming .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (04) :2839-2845
[33]   Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence [J].
Aggarwal, Bhumika ;
Gogtay, Jaideep .
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2014, 8 (03) :349-356
[34]   Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease? [J].
Grootendorst, DC ;
Gauw, SA ;
Baan, R ;
Kelly, J ;
Murdoch, RD ;
Sterk, PJ ;
Rabe, KF .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2003, 16 (02) :115-120
[35]   High-Dose N-Acetylcysteine in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease [J].
R. Zuin ;
A. Palamidese ;
R. Negrin ;
L. Catozzo ;
A. Scarda ;
M. Balbinot .
Clinical Drug Investigation, 2005, 25 :401-408
[36]   Acute effect of oral steroids on muscle function in chronic obstructive pulmonary disease [J].
Hopkinson, NS ;
Man, WDC ;
Dayer, MJ ;
Ross, ET ;
Nickol, AH ;
Hart, N ;
Moxham, J ;
Polkey, MI .
EUROPEAN RESPIRATORY JOURNAL, 2004, 24 (01) :137-142
[37]   Comparison of the effect of high-dose inhaled budesonide and fluticasone on adrenal function in patients with severe chronic obstructive pulmonary disease [J].
Fahim, Ahmed ;
Faruqi, Shoaib ;
Wright, Caroline E. ;
Kastelik, Jack A. ;
Morice, Alyn H. .
ANNALS OF THORACIC MEDICINE, 2012, 7 (03) :140-144
[38]   New Treatment Option for Chronic Obstructive Pulmonary Disease: Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler [J].
Self, Timothy H. ;
Ellingson, Samantha .
AMERICAN JOURNAL OF MEDICINE, 2017, 130 (11) :1251-1254
[39]   Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: A meta-analysis [J].
Liu, Baofeng ;
Zan, Shuangjiang ;
Luo, Weishun .
HEART & LUNG, 2022, 52 :52-60
[40]   Impact of Preliminary Bronchodilator Dose in Chronic Obstructive Pulmonary Disease Patients With Suboptimal Peak Inspiratory Flow [J].
Hassan, Mohamed Ismail ;
Laz, Nabila Ibrahim ;
Madney, Yasmin M. ;
Abdelrahim, Mohamed E. A. ;
Harb, Hadeer S. .
CLINICAL THERAPEUTICS, 2024, 46 (12) :e16-e24